amylin glp-1 dual agonist Can amylin-based drugs upstage agonists? Novo's GLP-1/Amylin Dual Agonist Amycretin

In a clinical trial, adults who switched from high-dose injectable obesity drugs to oral GLP-1 pill Foundayo were able to maintain most of their previous weight loss over 1 year, with relatively limited weight regain

Summary of product characteristics (Ozempic)

Read more here: To view or add a comment, sign in More from this author Explore related topics Explore content categories

Fasting glucose decreased significantly at all dose levels above 1mg

Screening and Article Selection Two independent researchers screened titles and abstracts of all retrieved studies based on the eligibility criteria

Long-acting formulations currently hold the largest GLP-1 Drug Market share at 57% due to their prolonged effects and ability to minimize patient dosing frequency